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UDP-galactose 40-epimerase results in a type III
galactosemia phenotype at birth†
Stephanie Paul,ab Thomas J. McCorvie,‡a Johannes Zschockec
and David J. Timson*adUDP-galactose 40-epimerase (GALE) is an essential enzyme in galactose
metabolism and its dysfunction results in type III galactosemia. Herein we
report a patient born with abnormal blood galactose levels and reduced
GALE activity who was shown to be heterozygous for a c.266C>T
missensemutation in theGALE gene, predicted to result in the amino acid
exchange p.A89V. Over a period of months, the patient's blood galactose,
galactose 1-phosphate and GALE activity levels reverted to normal,
encouraging us to investigate this mutation. Structurally Ala89 is a highly
conserved residue located close to the binding site of the cofactor, NAD+.
Consequentially molecular modelling predicted that this mutation results
in steric clashes between the cofactor and valine side chain, and bio-
informatic predictions suggested that p.A89V is likely to be less stable than
the wild-type. Biochemical studies on the recombinant p.A89V enzyme
demonstrated lower activity than the wild type (Km increased by approx-
imately 30-fold; kcat reduced approximately 180-fold), and additionally
changes in stability and altered NAD+ binding were observed. Thus,
a picture emerges in which this mutation leads to reduced stability,
disturbed cofactor binding and subsequently reduced activity. Overall this
study suggests that bioinformatics predictions are useful in assessing the
eﬀects of newly discovered mutations on enzyme function, but care
should be taken in extending predictions to the clinical phenotype espe-
cially in cases of heterozygosity. It also raises interesting questions about
a dominant negative eﬀect of some GALE missense alleles and potential
compensatory mechanisms occurring in people born with clinical
chemistry measurements suggesting a diagnosis of galactosemia.ersity Belfast, Medical Biology Centre, 97
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hemistry 2016Introduction
Type III galactosemia (OMIM#230350) is an inherited metabolic
disease caused by a deciency in the activity of UDP-galactose
40-epimerase (GALE, EC 5.1.3.2).1–3 This enzyme catalyses the
inter-conversion of UDP-galactose and UDP-glucose, a reaction
that is part of the Leloir pathway of galactose catabolism.4,5
Additionally GALE has a second role in maintaining the pools of
UDP-galactose and UDP-glucose (along with the related
metabolites, UDP-N-acetylgalactosamine and UDP-N-acetylglu-
cosamine), which are precursors in the synthesis of the sugar
moieties of glycoproteins and glycolipids. The enzyme is
a member of the short-chain dehydrogenase (SDR) family uti-
lising a bound NAD+ cofactor and in regards to type III galac-
tosemia the majority of mutations are missense, present
throughout its structure.3 There is a wide spectrum of symp-
toms associated with the disease ranging from increased
concentrations of galactose metabolites without clinical eﬀects
in the mildest forms to irreversible organ damage leading to
physical and cognitive disability in the most severe forms.1,6–8
Currently, the only treatment is the removal of galactose (and its
precursors such as lactose) from the diet. This treatment is
unsatisfactory since, for those with the most severe forms of the
disease, it only delays and reduces the extent of organ damage
but cannot prevent or reverse it.7
Biochemically, disease-associated mutations tend to reduce
the activity of the enzyme.9–12 There is an approximate correla-
tion between the extent of impairment in the turnover number
(kcat) and the severity of disease.10,12 The majority of mutations
alter residues away from the active site and the loss of activity is
most likely caused by altered protein stability rather than direct
eﬀects on the active site residues.9,10,12–17 Interestingly both
increased and decreased stability can be associated with
reduced activity and disease.17 GALE is a homodimer with one
molecule of NAD+ bound per subunit.18 This NAD+ is critical for
the enzyme's activity and, in some of the disease-associated
variants, one eﬀect of reduced aﬃnity for NAD+ is altered
stability.13,17,19,20RSC Adv., 2016, 6, 17297–17301 | 17297
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View Article OnlineTo date, relatively few disease-associated mutations have
been reported and GALE deciency is considered to be rare. The
incidence is strongly population dependent where it is esti-
mated to be 1 : 6700 in African Americans but approximately
1 : 64 800 in Americans of European descent.21 However, the
benign (asymptomatic) nature of the milder forms of the
disease may mean that there are a signicant number of
undetected cases in the general population. Here we report the
identication of a previously unreported mutation in GALE,
which was associated with type III galactosemia at birth along
with the characterisation of this variant protein. We also
demonstrate the strengths of using bioinformatics methods to
predict the biochemical eﬀects of this mutation.
Materials and methods
Molecular genetics
GALEmutation analysis was carried out by PCR amplication of
the coding exons and adjacent intron regions (RefSeq
NM_000403.3) followed by bidirectional Sanger sequencing
using standard methods. The genetic diagnostic analyses were
performed with full written informed consent in compliance
with the relevant laws and institutional guidelines.
Bioinformatics and molecular modelling
The crystal structures of human GALE with UDP-glucose and
UDP-N-acetylglucosamine bound (PDB: 1EK5 and 1HZJ18,22)
were energy minimised and solvated using YASARA.23 PyMol
(http://www.pymol.com) was used to alter residue 89 to valine in
both structures and the resulting variant structures re-
minimised using YASARA. The minimised models are pre-
sented as ESI data† to this paper and were used in subsequent
analyses. Accessible surface areas were calculated using
GETAREA (http://curie.utmb.edu/getarea.html)24 and root mean
squared deviations (RMSD) using the align function in PyMol.
Multiple sequence alignments were calculated using ClustalW25
using reviewed GALE sequences in UniProt (http://
www.uniprot.com). Conservation scores were obtained using the
Scorecons server (http://www.ebi.ac.uk/thornton-srv/databases/cgi-
bin/valdar/scorecons_server.pl)26 and SIFT tolerance scores from
http://si.jcvi.org/.27 Instability and aggregation tendencies were
estimated using SNP eﬀect 4.0 (http://snpeﬀect.switchlab.org/)28
and I-Mutant 3.0 (http://gpcr2.biocomp.unibo.it/cgi/predictors/I-
Mutant3.0/I-Mutant3.0.cgi) at 37 C and pH 8.8 in order to
match the conditions used in in vitro enzyme assays.29,30
Expression, purication and kinetic analysis of wild-type and
variant human GALE
Wild-type human GALE was expressed in, and puried from,
Escherichia coli HMS174(DE3) as previously described.10 The
coding sequence was altered so that codon 89 encoded valine
instead of alanine by site-directed mutagenesis using the
QuikChange method.31 The variant protein was expressed and
puried using the same protocol as the wild-type. Enzyme
activity was measured in 50 mM Hepes–OH, pH 8.8 at 37 C by
coupling the production of UDP-glucose to its oxidation in an17298 | RSC Adv., 2016, 6, 17297–17301NAD+-requiring reaction catalysed by UDP-glucose dehydroge-
nase.10,32 Recombinant human UDP-glucose dehydrogenase was
produced as previously described.16 Protein concentrations
were estimated by the method of Bradford using BSA as
a standard.33Analytical methods
Limited proteolysis was carried out using trypsin (10–900 nM
supplemented with 2 mM calcium chloride) and GALE (16 mM)
in a total volume of 10 ml. UDP-galactose (2 mM) was added as
required. Reaction mixes were pre-incubated at 37 C for 5 min
prior to addition of the protease. They were then incubated for
a further 30min at 37 C before being stopped by the addition of
an equal volume of SDS-PAGE loading buﬀer (125mMTris–HCl,
pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 1% (w/v) dithiothreitol,
0.002% (w/v) bromophenol blue) and heating at 95 C for
approximately 3 min. Reactions were analysed by 10% SDS-
PAGE.
Crosslinking of GALE (10 mM) with bis(sulphosuccinimidyl)
suberate (BS3, 0.1–800 mM) was carried out at 37 C in a reaction
volume of 10 ml. Reaction mixes were pre-incubated for 5 min
prior to the addition of crosslinker. Reactions were allowed to
proceed for another 30 min at 37 C before being stopped by
addition of an equal volume of SDS-PAGE loading buﬀer and
heating at 95 C for approximately 3 min. Reactions were ana-
lysed by 10% SDS-PAGE.
Melting temperatures (Tm) of GALE (5 mM) were estimated
(in triplicate) by diﬀerential scanning uorimetry (DSF) using
Sypro Orange (Sigma) as previously described.17,34 Fluorescence
spectra of GALE (200 ml of 20 mM) were collected in triplicate
using a Spectra Max Gemini X UV plate reader using an exci-
tation wavelength of 280 nm.Results and discussion
Clinical chemistry and molecular genetics
The female patient was tested for blood galactose in the
neonatal period. An initial reading of 34.2 mg dl1 was recorded
(normal values < 20 mg dl1). Eight days later this had dropped
slightly to 31.2 mg dl1. At six weeks, galactose 1-phosphate
levels were 6.3 mg/100 ml erythrocytes (normal < 1.5 mg/100 ml)
and GALE activity was 0.41 mmol h1 ml1 erythrocytes (normal
2.72–7.91 mmol h1 ml1 erythrocytes). Galactokinase and
galactose 1-phosphate uridylyltransferase activity were both in
the normal ranges. By eight months, galactose levels were
1.3 mg dl1 and galactose 1-phoshate levels were 0.98 mg dl1
(both within the normal range). At 21 months, galactose
1-phosphate had dropped further to 0.75 mg dl1. The patient is
developing normally without any treatment or dietary
intervention.
DNA sequencing revealed a heterozygous GALE variant
c.266C>T (rs201437329) which is predicted to cause replacement
of the amino acid alanine at residue 89 with valine, denoted
p.Ala89Val. Ala-89 is located in the NAD+ binding site (Fig. 1a).
The mutation has been registered with allele frequencies of 0.4%
(29/6604) and 0.01% (8/65 860), respectively, in Finnish and non-This journal is © The Royal Society of Chemistry 2016
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View Article OnlineFinnish European individuals (ExAC database accessed 23rd Sept
2015, http://exac.broadinstitute.org) but to our knowledge has not
yet been reported in a patient with GALE deciency. No other
alteration of potential functional relevance in the gene was
identied.
Bioinformatics and molecular modelling
Multiple sequence alignment showed that Ala89 is highly
conserved across GALE orthologues (ESI Fig. S1†). Indeed the
conservation score26 was 0.99 and the SIFT tolerance score27 was
0.0 indicating a highly conserved residue in a site that is
intolerant to this relatively conservative change. Molecular
modelling predicted no signicant change in the overall struc-
tures (RMSD of 0.297 A˚ and 0.345 A˚ for the UDP-glucose and
UDP-N-acetylglucosamine bound structures respectively) and
the accessible surface area of residue 89 was also similar (14.0–
15.6%) for both WT and p.A89V bound to both productFig. 1 Biochemical analysis of GALE p.A89V. (a) Ala89 is located in the NA
backbone; grey sticks, key residues forming hydrogen bonds with NAD
bonds. The image was generated in Chimera using PDB ﬁle 1EK5. (b) p.
represents the mean of three determinations of the rate and the error ba
linear ﬁt to the Michaelis–Menten equation. (c) p.A89V (16 mM) has redu
Results were analysed by 10% SDS-PAGE and the sizes of molecular mas
degradation fragments for WT and p.A89V GALE. Arrows indicate full-len
FRET. The lack of signal at 450 nm indicates there is no NAD+ cofactor b
error bar the standard deviation of those means.
This journal is © The Royal Society of Chemistry 2016molecules (ESI Table S1†). Ala89 is located in the NAD+ cofactor-
binding site, adjacent to the adenine moiety and the alteration
of this residue to valine introduces a larger side-chain that
results in a steric clash with the adenine moiety (Fig. 1a; ESI
Fig. S2†). This indicates a potential to disrupt cofactor binding.
Furthermore predictions with SNP eﬀect 4.0 and I-Mutant 3.0
suggested that p.A89V is less stable than the wild-type, with an
increased tendency to aggregate (ESI Table S2†). Collectively
when compared to similar analyses carried out on variants for
which the degree of enzymatic impairment is known,35 these
results suggest that p.A89V is likely to be severely impaired
compared to wild-type.
Biochemical analysis of recombinant p.A89V
To gain insight into the biochemical eﬀects of this mutation
p.A89V was produced recombinantly and puried. The variant
protein was substantially kinetically impaired compared to theD+ binding site of the protein, close to the adeninemoiety. Grey ribbon,
+; purple, Ala89; cyan, NAD+; black dashed lines, predicted hydrogen
A89V (7 mM) has impaired kinetics compared to wild-type. Each point
rs the standard deviations of these means. The line represents a non-
ced stability towards proteolytic digestion compared to the wild type.
s markers are shown to the left of the gel in kDa. Red asterisks indicate
gth GALE protein. (d) Detection of NAD+ binding in p.A89V (20 mM) by
ound. Each point represents the mean of three determinations and the
RSC Adv., 2016, 6, 17297–17301 | 17299
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View Article Onlinewild-type enzyme (Fig. 1b) with a Michaelis constant (Km)
increased almost 30-fold to 1900  960 mM (compared to 69 mM
for the wild-type10) and a turnover number (kcat) reduced 180-
fold to 0.2 s1. This is less than the value measured for the
p.V94M variant (1.1 s1; cf. the wild type value of 36 s1) which is
associated with severe forms of the disease.10
Like the wild-type, p.A89V formed homodimers as judged by
protein–protein crosslinking (data not shown), although there
was a signicant change in the protein's thermal stability (Tm of
48.8  0.7 C compared to 52.8  0.3 C for the wild-type under
the same conditions; p ¼ 0.0008, unpaired t-test).17 p.A89V was
also more susceptible to proteolysis by trypsin (Fig. 1c) where
the variant was degraded into more fragments and showed
noticeable degradation at a lower protease concentrations. Both
the wild-type and p.A89V were protected from this proteolysis in
the presence of UDP-galactose (ESI Fig. S3†). Moreover in the
wild-type protein, the bound NAD+ can be detected by FRET:
when GALE is excited at 280 nm there is a large uorescence
emission peak at 340 nm (resulting from tryptophan and
other aromatic residues) and a smaller peak at 450 nm
(resulting from the bound NAD+).17 In p.A89V, the rst peak was
observed, but not the second (Fig. 1d). Therefore recombinant
p.A89V, in contrast to the wild-type, likely does not contain
appreciable amounts of NAD+. This suggests that the variant
has reduced aﬃnity for the cofactor, which is likely to be the
main cause of the reduced stability towards proteases and the
loss of activity compared to the wild-type. Therefore any activity
that could be observed most likely results from the high
concentrations of NAD+ (4 mM), which are necessarily present
in the coupled enzyme assay.
Conclusions
Taken together, these results suggest that the ultimate cause of
the initial GALE deciency observed here results from the
additional bulk of the valine side chain compared to that of
alanine. This likely reduces the aﬃnity for NAD+ substantially,
and consequently the stability and activity of the protein. These
biochemical results largely validate the predictive framework
based on bioinformatic analyses that were previously proposed
to assess newly discovered mutations.35 The patient initially
presented with clinical chemistry measurements consistent
with a diagnosis of type III galactosemia, but she remained
asymptomatic and her metabolite and enzyme activity
measurements are now in the normal range.
Prolonged biochemical abnormalities andmarked reduction
in GALE activity are unusual in heterozygotes of GALE muta-
tions. As such no relevant second alteration (on the other allele)
was identied although a mutation in an intron, promoter or
a large structural aberration involving parts of the gene cannot
be excluded. Our analysis of the p.A89V mutation was not
successful in determining the cause of the patient's apparent
temporary galactosemic phenotype but it is possible that the
raised galactose and galactose 1-phosphate levels in the period
immediately aer birth in this patient could be due to a domi-
nant negative eﬀect. The eﬀects appear to have been more
pronounced in the neonatal period and it is likely that the17300 | RSC Adv., 2016, 6, 17297–17301patient's milk intake decreased over the period in question that
may provide a partial explanation although there may also be
other, as yet unidentied, compensatory mechanisms at the
cellular and molecular level. Nonetheless, in support of our
hypothesis, dominant negative eﬀects have been reported for
the GALE mutations p.N34S and p.L183P when heterozygously
expressed in a yeast model with the wild-type. These mutations
resulted in 37% and 24% respectively of the activity of strains
homozygous for wild-type GALE in contrast to the expected
50%.13 It also interesting to note that p.N34S aﬀects a residue
involved in NAD+ binding and p.L183P likely disturbs the
overall structure of this region of the protein35 suggesting a link
due to cofactor binding. Gaining insight into the structural and
biochemical basis of this dominant negativity should be
a priority for future research, especially as the majority of
individuals with type III galactosemia are compound heterozy-
gous.3 Such studies would give deeper insight into the role
allelic heterogeneity plays as a whole in many metabolic
disorders.
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